Stockwatch: Coronavirus Distorts The Shape Of Pfizer Results
What Was Supposed To Be Good PR Now Ripples Through Pfizer’s Financials
Pfizer’s results may have heralded a third-quarter stabilization of pandemic-related effects had the costs and expectations for its vaccine not hijacked sentiment.
You may also be interested in...
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.